About Eisbach
Eisbach is a company based in Planegg (Germany) founded in 2019 by Adrian Schomburg and Andreas Ladurner. Eisbach has raised $4.57 million across 4 funding rounds from investors including EIT Health, BMBF and Bayerisches Landesportal. Eisbach offers products and services including ALC1 Inhibitors and CHD1 Inhibitors.
- Headquarter Planegg, Germany
- Founders Adrian Schomburg, Andreas Ladurner
- SectorsHealthcare
- Email••••••••
- Website eisbach.bio
- Social LinkedIn X
- Legal Name Eisbach Bio Gmbh
- Total Equity Funding$4.57M (USD)
in 4 rounds
- Latest Funding Round$4.57M (USD), Series A
Mar 2024
- InvestorsEIT Health
& 3 more
Products & Services of Eisbach
Eisbach offers a comprehensive portfolio of products and services, including ALC1 Inhibitors and CHD1 Inhibitors.
Drugs targeting ALC1 to treat HRD tumors via synthetic lethality.
Inhibitors for PTEN-deficient cancers to induce synthetic lethality.
Funding Insights of Eisbach
Eisbach has successfully raised a total of $4.57M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $4.57 million completed in March 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $4.57M
- Total Rounds 4
- Last Round Series A — $4.57M
- Investors Count 4
All 4 funding rounds of Eisbach with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2024 | $4.57M | Series A | – | – | |
| Nov 2021 | $7.3M | Grant | – | – | |
| Jul 2021 | $9.47M | Grant | – | – | |
| Jun 2019 | – | Seed | – | EIT Health | – |
4 investors in total: 4 institutional.
Investors in Eisbach
Eisbach has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include EIT Health, BMBF and Bayerisches Landesportal.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
An investment fund focused on oncology therapies is managed. | – | cancerfocusfund.com | Houston, United States | |
Healthcare startups are accelerated and incubated through specialized programs. | 2015 | eithealth.eu | Munich, Germany | |
Access to government programs and development services is facilitated. | – | bayern.de | Munich, Germany | |
Education and research policies are overseen by the ministry. | 1955 | bmbf.de | Berlin, Germany |
Investor details for Eisbach
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Eisbach
5 people are tracked at Eisbach (4 in leadership, 1 in team).
| Name | Role | Group |
|---|---|---|
Adrian Schomburg | Co-Founder & CEO | Leadership |
Andreas Ladurner | Co-Founder | Leadership |
Jonathan Iorio | Director Of Finance | Leadership |
Markus Lechner | Associate Director Preclinical Development | Leadership |
Gunnar Knobloch | Principal Scientist Protein Chemistry | Team |
Complete people profiles for Eisbach
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Eisbach
3 dated milestones of Eisbach across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Eisbach is founded.
- Funding First funding round.
- Funding Latest funding round, Series A, of $4.6M.
Web traffic of Eisbach
The website of Eisbach (eisbach.bio) receives about 1.7K visits a month.
- Monthly visits1.7K
▲ 67.3% vs previous month
Websites whose visitors overlap most with Eisbach. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| viramed.de | 100% | – | – | View details | |
| biontex.com | 98% | – | #13,164,623 | View details | |
| project-pharmaceutics.com | 98% | – | – | View details | |
amicusrx.de | amicusrx.de | 97% | – | #10,724,948 | – |
| leukocare.com | 96% | 5.7K | #3,715,251 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 19 similar websites and full traffic analytics for Eisbach
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 19 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Eisbach
Complete news archive for Eisbach
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Eisbach
10 companies that operate in the same segment as Eisbach (Oncology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | 2002 | Saint-genis-pouilly, Ain, France | USD 56.13 M | USD 235.08 M | – | |
Developer of small molecule drugs for the treatment of cancer and inflammatory disease | 2008 | Natick, Massachusetts, United States | USD 98.4 M | USD 146.07 M | 279 | |
Small molecule therapeutics are developed for cancer and rare diseases. | 2017 | New York, New York, United States | USD 229.6 M | – | – | |
Small-molecule drugs for cancer treatment are developed via Degronimid platform. | 2016 | Cambridge, Massachusetts, United States | USD 223 M | USD 35.95 M | 110 | |
Developer of drugs based on T-Cell receptor technology for the treatment of cancer | 2008 | Abingdon, Oxfordshire, United Kingdom | USD 601.28 M | USD 400.95 M | 493 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Eisbach
Eisbach was founded in 2019.
Eisbach is headquartered in Planegg, Germany. It is registered at Planegg, Bavaria, Germany.
Adrian Schomburg is the current CEO of Eisbach. They have also founded this company.
Eisbach is a funded company, having raised a total of $4.57M across 4 funding rounds to date.
Eisbach was founded in 2019 in Planegg, Germany, within the biotechnology sector. Targeted therapies for cancer treatment are developed, focusing on tumor-suppressor mutants and genome-guided approaches. A proprietary assay technology is utilized, employing modified nucleosomal substrates to enable allosteric regulation of enzyme targets. Operations center on advancing these therapeutic modalities for oncology applications.
Eisbach offers ALC1 Inhibitors and CHD1 Inhibitors.
Eisbach has 4 investors. Key investors include EIT Health, BMBF, Bayerisches Landesportal, and Cancer Focus Fund.
Eisbach operates through Eisbach Bio Gmbh.